78495-63-3

Usage

Uses

Used in Pharmaceutical Industry:
2-Fluoro-6-methoxyphenylboronic acid is used as a reactant for the preparation of functionally selective allosteric modulators of GABAA receptors. These modulators play a crucial role in the treatment of various neurological and psychiatric disorders by targeting specific sites on the GABAA receptor, thus modulating its activity.
Used in Chemical Synthesis:
2-Fluoro-6-methoxyphenylboronic acid is used as a reactant in the Suzuki cross-coupling reaction, a widely employed method for the formation of carbon-carbon bonds. This reaction is essential in the synthesis of complex organic molecules, including those with potential applications in the pharmaceutical, agrochemical, and materials science industries.
Used in Cancer Research:
2-Fluoro-6-methoxyphenylboronic acid is used as a reactant in the preparation of inhibitors of the checkpoint kinase Wee1. Wee1 is a protein kinase involved in the regulation of the cell cycle, and its inhibition has been shown to have potential therapeutic benefits in the treatment of cancer.

InChI:InChI=1/C7H8BFO3/c1-12-6-4-2-3-5(9)7(6)8(10)11/h2-4,10-11H,1H3

Upstream product

• 150-46-9 triethyl borate 
• 456-49-5 1-fluoro-3-methoxybenzene 
• 75626-21-0 C₉H₁₂BFO₃ 

Downstream Products

• 1448866-35-0 5-(5-chloro-2-methyl-phenyl)-6-(4-chloro-2-methyl-phenyl)-2-(6-fluoro-2-methoxy-phenyl)-1-isopropyl-4-oxo-5,6,-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one 

Relevant academic research and scientific papers

IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND

The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2,2',2"-(1,3,5,2,4,6-trioxatriborinane-2,4,6-triyl)tris(3-fluorophenol), useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND

The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure (I), useful for the synthesis of compounds that target KRAS G12C mutations, such as (II).

COMBINATION THERAPY INCLUDING A KRASG12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS

The present invention provides combination therapy that includes an KRASG12C inhibitor, such as (see Formula), or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.

Substituted 3-amino biaryl propionic acids as potent VLA-4 antagonists.

A series of substituted N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl- and (L)-azetidyl-beta-biaryl beta-alanine derivatives was prepared as selective and potent VLA-4 antagonists. The 2,6-dioxygenated biaryl substitution pattern is important for optimizing potency. Oral bioavailability was variable and may be a result of binding to circulating plasma proteins.